Linagliptin noninferior to glimepiride in type 2 diabetes

June 28, 2012

(HealthDay) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.

Researchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.

Patients with type 2 diabetes may stop responding to metformin over time. Others who do not respond to metformin alone are given a second drug to help them maintain normal blood sugar levels. The researchers noted that which drug they should be prescribed is unclear.

The researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin. However, these drugs can sometimes lead to hypoglycemia and weight gain, which increases the patients' risk for heart attack and stroke.

To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years. The study, which was funded by linagliptin's maker, Boehringer Ingelheim, involved 1,500 people from 16 countries with type 2 diabetes. None of the patients had responded to metformin alone.

Although the effectiveness of the drugs were similar, the study showed the side effects of linagliptin were much less severe than those of glimepiride. The researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.

The patients on linagliptin also had fewer heart attacks and strokes compared to those being treated with glimepiride.

The researchers argued that since linagliptin allows the body to increase the amount of insulin it produces in a glucose-dependent way, the risk for hypoglycemia may be significantly lower.

And since hypoglycemia "can have substantial negative clinical consequences" in terms of risk for death, illness, mental function and poor quality of life, preventing it is crucial, study co-author Baptist Gallwitz, of Tubingen University Hospital, said in a news release.

The study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness. They added more research is needed to confirm their findings.

One expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.

The new study provides more evidence that drugs like linagliptin "are just as good as the old standby sulfonylurea therapies, with the added benefits of inducing fewer hypoglycemic events, causing less weight gain, along with a likely decrease in cardiovascular events," said Dr. Stuart Weiss, an endocrinologist at NYU Langone Medical Center and clinical assistant professor at the NYU School of Medicine, New York City.

But millions of Americans suffer from type 2 diabetes, so "cost issues favoring sulfonylureas may be the only reason for preferring continued sulfonylurea use," he added. The results of a larger, ongoing study currently underway may help resolve the issue of whether the newer drug is worth the extra money, Weiss said.

The study was published online June 27 in The Lancet.

Explore further: Added benefit of linagliptin is not proven

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Added benefit of linagliptin is not proven

January 6, 2012
Linagliptin (trade name: Trajenta) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled ...

Isomaltulose doesn't improve glycemic control in diabetes

April 13, 2012
(HealthDay) -- For patients with type 2 diabetes, substitution of sucrose with isomaltulose is not associated with improved glycemic control (measured by hemoglobin A1c [HbA1c] levels) at 12 weeks, according to a study published ...

New drug improves glucose control without increasing risk of hypoglycemia in type 2 diabetes patients

February 26, 2012
TAK-875, a new treatment for type 2 diabetes, improves glycaemic (blood sugar) control and is equally as effective as the sulphonylurea glimepiride (a common drug treatment) but has a significantly lower risk of hypoglycaemia ...

Bolus calculation, flexible insulin up diabetes control

February 24, 2012
(HealthDay) -- A structured course teaching the benefits of automated bolus calculator (ABC) use and flexible intensive insulin therapy (FIIT) improves metabolic control and satisfaction in patients with type 1 diabetes, ...

Early loss of glucagon response to hypoglycemia found in teens

June 22, 2012
(HealthDay) -- In adolescents with type 1 diabetes the glucagon response to hypoglycemia is lost as early as one month and at a median of eight months after diabetes diagnosis, according to a study published online June 14 ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.